Human epidermal growth factor receptor 2 (HER2) is overexpressed and/or amplified in 15-20% of all breast cancers, and is associated with an aggressive tumour type with impaired prognosis and a predictive marker for trastuzumab treatment. HER2 status can be determined by immunohistochemistry (IHC) at protein level and by fluorescence in situ hybridisation (FISH) analysing gene amplification, and it is recommended that it should be performed in all primary breast cancers. In a quality control study the reproducibility of HER2 status was assessed by distributing eleven breast tumours prepared on a tissue microarray to 25 pathology laboratories in Sweden in 2005 and 2006. The concordance between the laboratories indicated good reproducibility ...
INTRODUCTION: Overexpression of the human epidermal growth factor receptor 2 (HER2) as a result of H...
The human epidermal growth factor receptor-2 (HER2) protein has been associated with breast cancer p...
La surexpression du récepteur 2 du facteur de croissance épidermique humain (HER2) et/ou l’amplifica...
Background. HER2 is a treatment predictive factor for the effect of trastuzumab and associated with ...
Between 20 and 30 per cent of all breast cancers show an overexpression of the growth factor HER2 an...
The tests that are currently available for the measurement of overexpression of the human epidermal ...
HER2 gene amplification and receptor overexpression by tumors seems to be associated with poorer pro...
AbstractAccurate determination of human epidermal growth factor receptor-2 (HER2) status is essentia...
The human epidermal growth factor receptor 2 gene (HER2) is amplified in approximately 15%–20% of al...
Aims Eligibility for anti-human epidermal growth factor receptor 2 (HER2) treatments in breast cance...
Human epidermal growth factor receptor 2 (HER2) overexpression is present in approximately 15% of ea...
Human epidermal growth factor receptor-2 is an important and prognostic factors and one of the most ...
Accurate determination of human epidermal growth factor receptor-2 (HER2) status is essential for o...
Eligibility for anti-human epidermal growth factor receptor 2 (HER2) treatments in breast cancer req...
To investigate the concordance of detecting human epidermal growth factor receptor 2 (HER-2) status ...
INTRODUCTION: Overexpression of the human epidermal growth factor receptor 2 (HER2) as a result of H...
The human epidermal growth factor receptor-2 (HER2) protein has been associated with breast cancer p...
La surexpression du récepteur 2 du facteur de croissance épidermique humain (HER2) et/ou l’amplifica...
Background. HER2 is a treatment predictive factor for the effect of trastuzumab and associated with ...
Between 20 and 30 per cent of all breast cancers show an overexpression of the growth factor HER2 an...
The tests that are currently available for the measurement of overexpression of the human epidermal ...
HER2 gene amplification and receptor overexpression by tumors seems to be associated with poorer pro...
AbstractAccurate determination of human epidermal growth factor receptor-2 (HER2) status is essentia...
The human epidermal growth factor receptor 2 gene (HER2) is amplified in approximately 15%–20% of al...
Aims Eligibility for anti-human epidermal growth factor receptor 2 (HER2) treatments in breast cance...
Human epidermal growth factor receptor 2 (HER2) overexpression is present in approximately 15% of ea...
Human epidermal growth factor receptor-2 is an important and prognostic factors and one of the most ...
Accurate determination of human epidermal growth factor receptor-2 (HER2) status is essential for o...
Eligibility for anti-human epidermal growth factor receptor 2 (HER2) treatments in breast cancer req...
To investigate the concordance of detecting human epidermal growth factor receptor 2 (HER-2) status ...
INTRODUCTION: Overexpression of the human epidermal growth factor receptor 2 (HER2) as a result of H...
The human epidermal growth factor receptor-2 (HER2) protein has been associated with breast cancer p...
La surexpression du récepteur 2 du facteur de croissance épidermique humain (HER2) et/ou l’amplifica...